Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type (2 selected)

Type

Guidance programme

Advice programme

Showing 51 to 75 of 372

Guidance, NICE advice and quality standards in development
TitleTypeExpected publication date
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]Technology appraisal guidance
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]Technology appraisal guidanceTBC
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]Technology appraisal guidanceTBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]Technology appraisal guidance
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]Technology appraisal guidance
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]Technology appraisal guidanceTBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]Technology appraisal guidanceTBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]Technology appraisal guidance
Cardiometabolic disease prevention and treatment guidelinesNICE guidelineTBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]Technology appraisal guidanceTBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]Technology appraisal guidanceTBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]Technology appraisal guidance
Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failureNICE guidelineTBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]Technology appraisal guidanceTBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]Technology appraisal guidanceTBC
Cladribine for treating relapsing multiple sclerosis ID6263Technology appraisal guidance
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]Technology appraisal guidanceTBC
COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessmentHealth technology evaluationTBC
Colon cancer (adjuvant) - irinotecan [ID379]Technology appraisal guidanceTBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]Technology appraisal guidanceTBC
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]Technology appraisal guidance
Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]Technology appraisal guidance
CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attackDiagnostics guidance
Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]Technology appraisal guidance
Dapagliflozin for treating chronic kidney disease [ID6411]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All